porcin
epidem
diarrhea
viru
pedv
member
alphacoronavirida
genu
within
coronavirida
famili
caus
agent
porcin
epidem
diarrhea
diseas
mortal
rate
high
suckl
piglet
pedv
caus
sever
econom
loss
exist
decad
panzoot
start
renew
interest
develop
univers
vaccin
toward
pedv
report
detail
sever
design
chang
made
hepat
b
viru
core
antigen
hbcag
base
recombin
vaccin
strategi
effect
vivo
initi
sever
multiantigen
vaccin
candid
abl
elicit
antibodi
specif
three
four
bcell
epitop
insert
chimer
protein
howev
lack
viru
neutral
led
redesign
vaccin
focu
newli
redesign
vaccin
elicit
strong
immun
respons
ysnigvck
amino
acid
motif
pedv
genet
modifi
new
vaccin
candid
abl
elicit
strong
antibodi
ab
respons
ysnigvck
epitop
correl
increas
abil
neutral
co
strain
pedv
addit
locat
insert
pedv
epitop
within
vector
protein
shown
affect
immun
recognit
toward
nativ
hbcag
vaccin
porcin
epidem
diarrhea
viru
pedv
enter
viru
caus
sever
diarrhea
dehydr
depress
pedv
speci
within
alphacoronaviru
genu
previous
type
coronavirida
coronavirida
famili
nidoviral
order
instanc
pedv
began
earli
outbreak
rel
tame
small
sporad
panzoot
occur
begin
mutat
viru
led
increas
virul
strain
recent
outbreak
caus
sever
econom
loss
worldwid
well
introduct
diseas
north
america
unit
state
transmiss
pedv
occur
primarili
oralnas
rout
incub
time
pedv
vari
age
strain
origin
strain
take
day
viral
shed
detect
newborn
piglet
day
develop
symptom
pedv
includ
fecal
shed
within
h
infect
die
high
rate
within
day
caus
signific
econom
loss
swine
industri
success
replic
pedv
intestin
epitheli
cell
young
piglet
caus
malabsorpt
diarrhea
induc
decreas
efficaci
brush
border
membranebound
digest
enzym
leaki
junction
small
intestin
symptom
sever
enough
case
result
death
rate
nearli
upon
exposur
due
dehydr
true
adult
pig
howev
may
due
delay
infect
matur
microvilli
typic
genom
coronavirida
contain
untransl
region
utr
contain
rang
open
read
frame
orf
pedv
approxim
kb
genom
orf
arrang
order
spike
protein
envelop
e
protein
membran
glycoprotein
nucleocapsid
n
protein
coronavirus
protein
undergo
posttransl
modif
includ
cleavag
domain
true
pedv
convent
separ
protein
domain
around
amino
acid
aa
recent
research
recombin
vaccin
pedv
predominantli
focus
protein
particular
attent
paid
domain
two
known
small
linear
bcell
epitop
within
domain
correspond
aa
sequenc
ysnigvck
sqygqvki
origin
strain
addit
small
bcell
epitop
discov
within
domain
correspond
aa
sequenc
gprlqpi
fourth
short
linear
bcell
epitop
locat
protein
correspond
sequenc
wafyvr
hepat
b
viru
core
antigen
hbcag
popular
protein
express
e
coli
use
vaccin
develop
result
protein
abl
assembl
viruslik
particl
vlp
vitro
purif
use
chimer
form
foreign
antigen
virus
insert
protein
genet
effici
immun
system
present
vlp
platform
hbcag
typic
divid
two
separ
domain
chimer
protein
design
chang
ntermin
ctermin
domain
occur
around
insert
foreign
epitop
near
residu
higher
immunogen
respons
compar
ntermin
ctermin
insert
site
identifi
major
immunodomin
region
mir
previou
work
lab
use
hbcag
vector
protein
novel
pedv
vaccin
strategi
origin
experi
five
treatment
vaccin
design
includ
four
candid
four
ysnigvck
sqygqvki
gprlqpi
wafyvr
linear
bcell
epitop
insert
individu
mir
fifth
candid
four
epitop
togeth
linear
peptid
sequenc
insert
mir
hbcag
backbon
protein
result
epitop
antibodi
ab
titer
measur
elisa
strongli
correl
viru
neutral
except
ysnigvck
motif
therefor
conclud
immun
respons
particular
antigen
pedv
might
critic
other
viru
neutral
inclus
ysnigvck
epitop
futur
vaccin
design
could
therefor
critic
efficaci
report
focus
sever
design
chang
previou
hbcagbas
pedv
vaccin
effort
improv
exposur
insert
pedv
epitop
immun
system
increas
overal
immun
respons
elimin
three
residu
mir
hbcag
protein
pi
report
increas
immun
respons
insert
epitop
modif
perform
vaccin
candid
fig
fig
addit
flexibl
watersolubl
residu
foreign
epitop
insert
mir
also
test
two
vaccin
candid
increas
solubl
present
includ
antigen
fig
substitut
two
residu
hbcag
vector
protein
two
vaccin
candid
fig
g
test
increas
efficaci
assembl
hbcagbas
vlp
substitut
previous
shown
lu
et
al
add
network
disulfid
coval
bond
pentam
hexam
lead
increas
structur
stabil
nativ
vlp
shown
fig
c
addit
disulfid
bond
shown
red
fig
final
locat
epitop
gprlqpi
wafyvr
chang
includ
ysnigvck
motif
mir
assembl
vlp
vaccin
design
chang
perform
test
vivo
first
anim
trial
fig
second
anim
trial
fig
eg
plasmid
construct
perform
use
plasmid
novagen
madison
wi
briefli
gene
code
optim
sequenc
idt
coralvil
ia
protein
amplifi
contain
overlap
sequenc
correspond
placement
vector
plasmid
gene
use
amplifi
plasmid
contain
gene
interest
circular
plasmid
transform
e
coli
express
neb
cell
use
heat
shock
method
construct
verifi
sanger
sequenc
transform
correct
sequenc
codon
usag
overnight
cultur
e
coli
cell
grown
lb
media
supplement
lgml
kanamycin
use
inocul
l
batch
yt
media
supplement
antibiot
rate
vv
e
coli
cultur
incub
od
reach
au
protein
product
induc
mm
isopropyl
iptg
cell
incub
overnight
result
cell
centrifug
store
purif
protein
purif
perform
previous
describ
briefli
cell
pellet
resuspend
sonic
pb
protein
asid
dhbcag
locat
inclus
bodi
protein
denatur
urea
load
onto
anion
exchang
chromatographi
aex
column
util
deae
sepharos
ff
resin
ge
healthcar
marlborough
eluent
ph
adjust
load
onto
immobil
metal
affin
chromatographi
imac
column
follow
imac
purif
stepwis
dialysi
perform
pb
ph
addit
addit
order
sarkosyl
sarkosyl
sarkosyl
sarkosyl
pb
vaccin
candid
diafilt
pb
buffer
use
spin
x
uf
tube
molecular
weight
cut
kda
corn
corn
ny
concentr
vaccin
pb
steril
filter
mm
lm
syring
filter
celltreat
pepperel
follow
adjuv
addit
dilut
steril
pb
dosag
ml
contain
lg
vlp
final
vaccin
first
anim
trial
contain
lg
protein
pb
ph
lg
per
dose
chitosan
invivogen
candid
formul
second
experi
total
lg
protein
pb
ph
lg
alhydrogel
invivogen
vaccin
candid
held
h
readi
use
vaccin
dosag
chosen
previou
studi
zetas
nano
malvern
instrument
malvern
uk
instrument
use
accord
manufactur
instruct
particl
size
distribut
measur
pb
initi
confirm
vlp
assembl
formvar
coat
copper
grid
treat
protein
sampl
second
grid
blot
filter
paper
allow
dri
sampl
stain
phosphotungst
acid
ph
second
stain
blot
filter
paper
allow
dri
imag
taken
use
jeol
peabodi
microscop
maximum
protein
sampl
prepar
analysi
ad
water
nupag
reduc
agent
invitrogen
carlsbad
ca
nupag
ld
buffer
invitrogen
total
per
well
nonreduc
sampl
prepar
similarli
substitut
water
reduc
agent
sampl
put
nupag
tm
bistri
page
gel
invitrogen
along
precisionplu
tm
protein
ladder
biorad
hercul
ca
gel
run
me
buffer
invitrogen
electrophoresi
gel
rins
three
time
mx
water
min
gel
treat
simplyblu
tm
safestain
invitrogen
least
one
hour
rins
water
overnight
imag
stain
gel
taken
use
chemidoc
touch
imag
biorad
densitometri
measur
perform
use
imagelab
softwar
biorad
densitometri
read
consid
pure
enough
proceed
anim
trial
western
blot
perform
use
protocol
reduc
page
sampl
precis
plu
westernc
protein
ladder
biorad
gel
load
cell
lysat
per
well
gel
blot
onto
nitrocellulos
membran
use
transblot
turbo
tm
instrument
biorad
accord
manufactur
instruct
membran
block
least
one
hour
use
nonfat
dri
milk
tbst
wash
perform
step
consist
three
fiveminut
rins
tbst
membran
treat
primari
mous
antihistag
antibodi
thermo
follow
secondari
hrp
conjug
goat
antimous
antibodi
millipor
billerica
detect
done
use
chemidoc
touch
instrument
biorad
clariti
ecl
substrat
biorad
endotoxin
level
test
remov
deterg
chaotrop
agent
test
perform
use
pierc
lal
chromogen
endotoxin
quantit
kit
thermo
kit
use
accord
manufactur
instruct
endotoxin
cut
level
euml
anim
experi
perform
accord
guidelin
approv
virginia
tech
institut
anim
care
use
committe
iacuc
group
germ
free
balbc
mice
charl
river
use
vivo
experi
week
old
mice
allow
acclim
day
prior
day
blood
draw
via
submandibular
bleed
vaccin
candid
two
neg
control
dhbcag
pb
administ
intraperiton
day
day
day
blood
sampl
collect
day
via
cheek
punch
method
day
exsanguin
collect
blood
sampl
incub
h
centrifug
aliquot
supernat
made
requir
frozen
test
ab
titer
insert
foreign
epitop
measur
previous
describ
process
util
custom
design
purifi
elisa
fusion
protein
efp
protein
use
coat
dilut
lgml
coat
buffer
mm
na
co
mm
nahco
ph
plate
coat
h
wash
block
overnight
serum
sampl
day
serial
dilut
block
buffer
start
dilut
appli
h
room
temperatur
rt
plate
next
incub
goat
antimous
igg
hrp
millipor
billerica
visual
done
tmb
one
compon
microwel
substrat
southernbiotech
read
nm
use
biotek
synergi
htx
plate
reader
winooski
vt
titer
calcul
reciproc
dilut
test
sera
measur
statist
similar
pb
neg
control
sampl
n
locat
plate
acinetobact
phagederiv
vlp
express
purifi
plasmid
pedv
vaccin
candid
use
process
differ
fraction
collect
aex
protein
assembl
elisa
plate
coat
vlp
protein
perform
dilut
efp
coat
plate
process
wv
elisa
process
use
adapt
thoma
et
al
microlon
flat
bottom
plate
coat
isol
co
strain
usda
aphi
ame
ia
pedv
concentr
tcid
dilut
steril
pb
h
plate
wash
steril
tb
plate
block
bsa
overnight
follow
wash
murin
serum
sampl
dilut
tb
well
fill
dilut
serum
serum
sampl
allow
incub
h
rt
wash
steril
tb
well
next
treat
volum
dilut
goat
antimous
igg
hrp
conjug
millipor
h
rt
wash
tb
well
detect
tmb
one
compon
microwel
substrat
southernbiotech
reaction
stop
use
sulfur
acid
biotek
synergi
htx
plate
reader
use
read
plate
nm
pedv
vn
titer
measur
use
focu
form
assay
ffa
describ
previous
execut
anim
diseas
research
diagnost
laboratori
veterinari
biomed
scienc
depart
south
dakota
state
univers
briefli
serum
sampl
heattreat
dilut
minim
essenti
medium
mem
lgml
tosyl
phenylalanyl
chloromethyl
keton
tpck
trypsin
serial
dilut
perform
plate
memtpcktrypsin
diluent
cell
cultur
adapt
pedv
ad
foci
form
unit
ffu
incub
h
result
mixtur
ad
confluent
monolay
cell
incub
h
new
well
wash
memtpcktrypsin
allow
incub
h
plate
fix
aceton
stain
fluorescein
isothiocyan
fitc
conjug
mab
visual
end
point
titer
determin
lowest
concentr
result
greater
reduct
fluoresc
rel
control
jmp
pro
softwar
sa
cari
nc
use
statist
analysi
sampl
run
nest
experiment
design
use
administr
peptideprotein
group
respect
individu
anova
contrast
perform
determin
statist
signific
individu
group
vaccin
use
vivo
test
success
purifi
fig
discuss
supplement
materi
abl
form
vlp
indic
dynam
light
scatter
data
shown
transmiss
electron
microscop
tem
imag
fig
complet
first
anim
trial
fig
immun
respons
seen
sqsgqvki
gprlqpi
wafyvr
epitop
seen
fig
two
three
test
vaccin
group
compar
dhbcag
control
hbcag
mhbcag
case
epitopespecif
ab
titer
increas
dosedepend
manner
cours
experi
data
shown
import
note
respons
seen
ysnigvck
motif
minim
nonexist
fig
lack
respons
ysnigvck
motif
may
indic
interact
take
place
residu
mir
test
candid
reduc
elimin
present
ysnigvck
epitop
second
anim
trial
fig
alum
includ
formul
three
vaccin
candid
effort
test
efficaci
adjuv
fig
indic
addit
alum
formul
detriment
vaccin
efficaci
measur
immun
respons
ysnigvck
epitop
comparison
hbcag
se
candid
vaccin
without
alum
ad
phenomenon
appear
hold
true
hbcag
ssm
candid
well
interestingli
addit
alum
appear
disrupt
respons
mhbcag
ssm
vaccin
ident
hbcag
ssm
vaccin
except
mutat
result
indic
addit
cystein
residu
enabl
mhbcag
ssm
vaccin
candid
invok
immun
respons
even
presenc
alum
possibl
due
ad
network
disulfid
bond
howev
ineffici
antigen
present
mir
hbcag
ssm
candid
due
peptid
interact
rule
contribut
factor
low
ab
respons
level
mhbcag
ssm
candid
also
abl
elicit
immun
respons
ntermin
gprlqpi
ctermin
wafyvr
epitop
seen
fig
c
similar
first
anim
trial
ab
titer
treatment
increas
dose
depend
manner
throughout
experi
data
shown
great
concern
recombin
product
chimer
proteinbas
vaccin
preexist
ab
vector
protein
may
caus
elimin
vaccin
prior
antigen
present
ab
titer
specif
dhbcag
protein
therefor
test
conjunct
individu
epitop
insert
result
fig
indic
ab
titer
dhbcag
statist
similar
across
treatment
first
anim
trial
indic
vaccin
induc
immun
respons
though
necessarili
insert
epitop
fig
second
anim
trial
fig
howev
data
suggest
two
vaccin
candid
epitop
insert
ntermin
histidin
tag
hbcag
ssm
mhbcag
ssm
significantli
lower
ab
respons
dhbcag
compar
treatment
elucid
immun
respons
vector
protein
ab
titer
unrel
vector
protein
contain
ntermin
histidin
tag
cleavag
site
test
describ
materi
method
section
fig
indic
vaccin
elicit
significantli
higher
ab
titer
histidin
tag
vaccin
foreign
epitop
insert
ntermin
histidin
tag
hbcag
ssm
mhbcag
ssm
follow
pattern
ab
titer
whole
dhbcag
protein
togeth
data
demonstr
histidin
tag
locat
nterminu
vaccin
candid
may
play
larg
role
ab
recognit
protein
seen
previous
other
placement
epitop
ntermin
tag
may
reduc
immun
interact
test
efficaci
vaccin
candid
respons
murin
serum
viru
determin
foci
form
assay
ffa
util
co
strain
pedv
fig
show
vn
titer
first
anim
trial
although
statist
signific
three
test
group
hbcag
hbcag
mhbcag
neg
control
dhbcag
pb
number
remain
rel
low
serum
sampl
second
anim
trial
fig
demonstr
stronger
abil
neutral
viru
two
treatment
group
hbcag
se
mhbcag
ssm
combin
peptid
ab
titer
data
demonstr
strong
correl
high
vn
titer
high
ab
titer
ysnigvck
epitop
fig
compar
gprlqpi
epitop
fig
determin
low
bind
affin
ab
gener
recombin
vaccin
nativ
protein
virion
could
contribut
vn
discrep
wv
elisa
assay
perform
serum
sampl
fig
treatment
wv
elisa
result
appear
correl
well
individu
peptid
elisa
result
independ
specif
ab
gener
candid
high
ab
titer
bcell
epitop
pedv
hbcag
hbcag
mhbcag
fig
hbcag
se
mhbcag
ssm
alum
fig
significantli
higher
absorpt
signal
dhbcag
pb
treatment
data
indic
peptid
present
vector
protein
prevent
elicit
ab
could
bind
viru
viru
neutral
assay
may
true
differ
abil
ysnigvck
neutral
pedv
compar
gprlqpi
origin
goal
project
improv
upon
vaccin
design
made
test
previous
pedv
design
modif
increas
antigen
present
viru
neutral
per
dose
basi
elimin
pi
residu
addit
serin
residu
foreign
epitop
test
first
anim
trial
reveal
major
flaw
either
modif
prevent
present
ysnigvck
epitop
hypothes
phenomenon
due
residu
interact
mir
vlp
modif
predict
increas
flexibl
region
newli
ad
flexibl
might
therefor
remov
small
ahelix
nativ
vector
protein
allow
new
interact
take
place
treatment
abl
gener
ab
bcell
epitop
vector
protein
indic
assembl
vlp
antigen
present
inde
take
place
vn
titer
vaccin
candid
signific
low
indic
high
ab
titer
sqsgqvki
gprlqpi
wafyvr
epitop
necessarili
associ
viru
neutral
preliminari
data
mind
focu
second
experi
twofold
test
use
alum
adjuv
attempt
two
redesign
increas
immun
respons
ysnigvck
epitop
maintain
immun
respons
gprlqpi
wafyvr
bcell
epitop
although
neutral
key
measur
may
benefit
includ
multipl
conserv
antigen
vaccin
futur
mutat
strain
hbcag
se
protein
use
posit
control
second
anim
trial
two
differ
formul
addit
alum
formul
hbcag
se
treatment
group
appear
detriment
immun
respons
indic
lack
ysnigvckspecif
ab
adjuv
vaccin
fig
interestingli
hbcag
se
alum
treatment
group
capabl
induc
respons
dhbcag
fig
possibl
recognit
histidin
tag
fig
togeth
data
indic
hbcag
se
vlp
assembl
success
ysnigvck
antigen
present
prior
formul
alum
antigen
present
reduc
upon
formul
lead
ab
recognit
vector
protein
alon
use
alum
ip
vaccin
deliveri
may
inde
reduc
immun
respons
seen
chang
et
al
cuba
et
al
also
indic
ip
vaccin
deliveri
vlp
may
best
rout
drainag
lymph
node
might
reduc
exposur
foreign
antigen
includ
vlp
design
howev
complet
elimin
immun
respons
foreign
antigen
similar
immun
respons
vector
protein
indic
may
addit
factor
present
within
studi
futur
vivo
work
may
therefor
requir
detail
analysi
administr
rout
possibl
variabl
vaccin
improv
also
signific
immun
respons
differ
seen
two
redesign
vaccin
candid
hbcag
ssm
mhbcag
ssm
second
anim
trial
mhbcag
ssm
vaccin
cystein
substitut
gener
ab
specif
three
pedv
epitop
includ
fig
abl
neutral
viru
fig
nonsubstitut
version
elicit
immun
respons
vector
protein
alon
fig
sole
differ
hbcag
ssm
mhbcag
ssm
candid
design
vector
protein
locat
away
mir
nonreduc
page
analysi
fig
along
tem
imag
fig
indic
issu
assembl
hbcag
ssm
vlp
differ
immun
respons
therefor
seem
indic
cystein
residu
improv
antigen
present
mhbcag
ssm
vaccin
possibl
due
increas
vlp
stabil
report
lu
et
al
hypothes
increas
stabil
give
mhbcag
ssm
vaccin
higher
halflif
vivo
lead
prolong
antigen
present
howev
hypothesi
investig
placement
gprlqpi
foreign
epitop
ntermin
histidin
tag
two
vaccin
candid
hbcag
ssm
mhbcag
ssm
correl
reduc
immun
reaction
dhbcag
compar
treatment
test
fig
b
ab
respons
histidin
tag
separ
dhbcag
case
histidin
tag
use
purif
dhbcag
coat
protein
use
assay
howev
elisa
valu
unrel
protein
contain
ntermin
sequenc
show
similar
pattern
amongst
treatment
group
fig
indic
placement
foreign
epitop
upstream
may
reduc
ab
recognit
histidin
tag
result
may
make
physiolog
sens
extend
nterminu
dhbcag
protein
form
spike
upon
vlp
assembl
possibl
antigen
locat
within
region
includ
histidin
tag
would
opportun
interact
immun
cell
ntermin
placement
desir
epitop
within
region
may
therefor
caus
preferenti
interact
insert
foreign
epitop
immun
system
compar
tag
seem
unlik
chang
remov
pi
ctermin
addit
wafyvr
epitop
would
influenc
detect
histidin
tag
rule
possibl
present
result
fig
b
indic
high
ab
respons
ysnigvck
epitop
higher
signific
vaccin
design
viru
neutral
compar
bcell
epitop
use
studi
b
fig
vn
wv
elisa
foci
form
assay
ffa
whole
viru
elisa
use
determin
serum
ab
titer
specif
co
strain
pedv
sera
collect
day
treatment
group
first
anim
trial
b
second
anim
trial
test
pedv
neutral
vitro
serum
sampl
subsequ
test
abil
bind
pedv
without
neutral
measur
c
treatment
group
mean
titer
compar
dhbcag
pb
neg
control
anova
analysi
standard
error
bar
shown
treatment
group
p
p
p
although
sever
design
chang
made
two
anim
trial
outlin
report
individu
epitop
ab
concentr
measur
use
assay
furthermor
signific
ysnigvck
motif
implic
previou
report
lab
well
other
inclus
bcell
epitop
ysnigvck
vaccin
pedv
elicit
ab
multipl
peptid
sequenc
without
increas
vn
titer
result
would
make
sens
viru
neutral
depend
upon
concentr
ab
specif
ysnigvck
peptid
sequenc
mean
addit
epitop
specif
ab
diminish
return
sinc
apoptosi
piglet
intestin
epitheli
cell
primari
concern
viru
neutral
utmost
import
one
possibl
explan
discrep
vn
titer
could
fundament
differ
gprlqpi
amino
acid
present
context
recombin
vlp
compar
nativ
pedv
viru
differ
exist
would
expect
ab
gener
e
coli
express
protein
would
reduc
neglig
bind
pedv
virion
howev
wv
elisa
result
fig
demonstr
strong
correl
epitop
ab
titer
wv
titer
independ
antigen
sequenc
thu
seem
though
preferenti
neutral
ysnigvck
epitop
true
phenomenon
vn
result
report
base
system
igg
level
murin
model
result
may
therefor
correl
directli
prevent
viral
infect
mesenter
epithelia
suckl
piglet
without
develop
howev
result
herein
help
demonstr
improv
efficaci
vaccin
gener
neutral
ab
toward
pedv
futur
studi
build
result
therefor
includ
strategi
enhanc
lactogen
immun
pregnant
sow
form
secretori
iga
specif
ysnigvck
antigen
